KEYWORDS cancer care facilities; catheter-related infections; vascular access devices Background/Purpose: Cytotoxic chemotherapy via central venous access ports is an important part of the standard treatment for most cancers, but it is accompanied with the risk of infections. This study aimed to analyze the incidence and risk factors for central venous access port-related infection (CPI) among Chinese patients receiving cytotoxic chemotherapy. Methods: Between January 1, 2002 and December 31, 2005 a total of 1391 cancer patients with 1449 totally implantable central venous access ports were evaluated. The log-rank test and Cox proportional hazards model were used for the analyses of risk factors. Results:
Introduction
Cytotoxic chemotherapy is an important part of the standard treatment for most cancers. To avoid frequent venipunctures, which are increasingly difficult after multiple courses of chemotherapy, and to facilitate the administration of continuous infusional chemotherapy, it is common to insert totally implantable central venous access ports. 1, 2 However, central port-related bacteremia and fungemia, including catheter tunnel infection, pocket infection in port devices, and skin-site infection, remain a challenging issue for clinicians. The incidence rate of central port-related infections (CPI) has been reported to vary from 7% to 19%. 3, 4 Many risk factors for CPI have been reported, including hematological malignancy, neutropenia, chronic steroid use, lacking perioperative antibiotic use, pancreatic cancer, poor performance status, previous infection, parenteral nutrition, immediate palliative care after implantation, and an inexperienced surgeon. 5e8 Considering the evolution of new materials in the make-up of central port devices, and prolonged cancer survival resulting in longer period of chemotherapy, it is possible that the incidence of CPI and associated risk factors have changed. The aim of this study was to examine the incidence and risk factors for CPI among Chinese patients receiving cytotoxic chemotherapy.
Methods

Patient population and implanted devices
Between January 1, 2002 and December 31, 2005 a total of 1391 cancer patients receiving 1449 totally implantable central venous access ports at Chang Gung Memorial Hospital, Chiayi, Taiwan were evaluated. All the devices had been used for at least one cycle of intravenous antineoplastic chemotherapy administration. Electronic medical records provided patient age, sex, disease status, primary tumor location, chemotherapy setting, time of catheter insertion, and the cause of catheter failure. All patients were followed up until death, last port removal, or until December 31, 2006, whichever came first. Port implantation was performed by well-trained surgeons in the operating room. The catheter tip was inserted in the superior vena cava under fluoroscopic guidance. Local anesthesia (10 mL of 2% mepivacaine hydrochloride) was administered for most patients during the implantation of the central venous access ports. General anesthesia was used only when a central port was implanted in conjunction with another major surgery. Prophylactic perioperative antibiotics (a single dose of cefazolin) was administered routinely. The surgical approach was either cephalic cut-down or subclavian vein puncture on either side, depending on the surgeon's preference. Implantation from the jugular or femoral vein system was performed only when the cephalic and subclavian vein systems failed. The port was fixed to the underlying pectoral muscle fascia with a single, nonabsorbable suture. Filling of the port system with diluted heparin saline was performed at the end of each procedure. The port was routinely flushed with diluted heparin saline by trained oncology nurses, following the administration of chemotherapy agents. The device was then maintained by flushing with a heparinized solution every 4e8 weeks without using any prophylactic antibiotics. Noncoring Huber needles were utilized for all injections.
Central port-related infection (CPI) and risk factors
Blood cultures were collected from port and peripheral veins in patients who had clinical symptoms or signs of infection (fever > 38 C, chills, or leukocytosis). A diagnosis of CPI was made based on at least one set of positive blood cultures from the catheter tip upon removal, > 10-fold increase in colonyforming units (CFU) per mL of blood aspirated from the port in comparison to peripheral blood cultures, or > 1000 CFUs of bacteria cultured through the device in the absence of peripheral blood cultures. In addition, clinical signs such as local cutaneous erythema, induration, or purulent discharge from the port pocket, and resolution of fever or sepsis after catheter removal also suggested CPI despite a negative culture. 9e13 All occurrences of CPI were stratified by patient age, sex, primary tumor type, and chemotherapy setting. Chemotherapy settings were divided into two groups, adjuvant and nonadjuvant. Adjuvant settings included ports for adjuvant chemotherapy (chemotherapies given after main treatment, such as curative surgery or concurrent chemoradiotherapy with the goal to prevent recurrence) and neo-adjuvant chemotherapy (chemotherapies given before main treatment with the goal to reduce tumor size or prevent tumor spreading). Ports for chemotherapy for metastatic disease or other curative intent were regarded as nonadjuvant. Catheter longevity was defined as the number of days the device remained in situ and the time from catheter insertion until removal due to infection, vessel or device thrombosis, device breakage, the completion of chemotherapy (in adjuvant and curative settings), death, or until December 31, 2006. Incidence of CPI was estimated as the number of infectious episodes per 1000 catheter-days. Infection-free catheter longevity was defined as the duration between port implantation and the development of an infection or last follow-up date.
Statistical analysis
Continuous variables were presented as mean AE standard deviation. The number of days for which a catheter remained in place was expressed as the median with the standard error due to censoring. The log-rank test and Pearson's Chi-square test was used to evaluate differences in catheter longevity and infection rate between sexes, types of malignancy, and chemotherapy settings. The Cox proportional hazards model was used to simultaneously examine all risk factors. A p value < 0.05 indicated statistical significance. All statistical analyses were performed using IBM SPSS 
Results
Incidence of CPI among primary malignancies
A total of 1449 central venous access ports were implanted in 1391 patients, including 1288 solid tumors (93%) and 103 hematological malignancies (7%), for at least one cycle of intravenous chemotherapy between January 1, 2002 and December 31, 2005. Taken together, there were 899 port implantations in 862 male patients (62%) and 550 port implantations in 529 female patients (38%). Forty-seven patients had more than one port implantation. The median patient follow-up time was 17.3 months [95% confidence interval (CI) 16.7e18.0 months]. The mean age was 59.8 AE 13.1 years (range, 13e91 years). The median catheter longevity was 16.6 months (95% CI 16.0e17.3 months) and total catheter-days were 723,192 catheter-days. As shown in Table 1 , patients with hematological malignancies had a higher incidence of CPI compared with patients with solid tumors. Chemotherapy in nonadjuvant settings was associated with a higher incidence of CPI compared with adjuvant settings. The overall CPI incidence was 0.21 per 1000 catheter-days (149 catheter infection episodes over 723,192 catheter-days; Table 2 ). Of these patients, hematological, head and neck, and gynecological cancers were the three major sites associated with higher risk for CPI compared with other primary cancers.
Risk factors for CPI
The univariate analysis revealed possible factors associated with a higher CPI, these included age, sex, site of the primary malignancy, and chemotherapy setting. However, in the multivariate analysis, age and sex were not significant risk factors. The site of primary malignancy and chemotherapy setting remained significant risk factors for CPI. Patients with head and neck, hematological, and gynecological cancers had the highest risk (p < 0.001) compared with patients with colorectal cancers. Central ports for adjuvant chemotherapy had a lower risk for infection than nonadjuvant setting (p < 0.001; Table 3 ). Overall, patients with solid tumors had longer infection-free catheter longevity compared with those with hematological malignancies (p < 0.001, Figure 1 ). In solid tumors, head and neck cancer (HNC) was associated with less infection-free catheter longevity than nonhead and neck (nonHNC) cancers (p < 0.001, Figure 2 ).
Microorganisms isolated from infected ports and catheters
In 149 episodes of diagnosed central port-related infection, Gram-negative bacteria were the most common pathogens (34.9%), followed by Gram-positive bacteria (16.7%), and fungi (16.1%). Furthermore, 48 cases (32.2%) diagnosed as CPI had a negative culture (Table 4 ). In Gram-negative bacteria, Pseudomonas aeruginosa (15.4%) and Enterobacteriae spp. (12.7%) were the most common pathogens.
Staphylococcus spp. (14.7%) was the predominant Grampositive pathogen. The fungus isolated included Candida spp. (9.4%) and other yeast-like organisms (6.7%).
Discussion
Among the currently evaluated 1391 patients (1449 ports), the overall incidence rate of CPI was 0.21 per 1000 catheter-days. As reported in the literature, the incidence of CPI ranged from 0.091 per 1000 catheter-days to 2.77 per 1000 catheter-days, 8, 14, 15 and most of the studies were retrospective investigations. The variation could be attributed to differences in the examined patient population. For example, a significant increased risk of CPI in patients with hematological malignancies (hazard ratio 4.00; p < 0.001) and HNC (hazard ratio 4.11; p < 0.001) compared with patients with colorectal cancer (hazard ratio Z 1) was observed. Noticeably, hematological malignancies and HNC were associated with significantly less infection-free catheter longevity compared with other cancer types (p < 0.001). In a prospective study, Mollee et al 16 also reported hematological malignancies may confer a greater risk for CPI than solid tumors. Long duration of neutropenia, 17, 18 immunosuppression, and frequent catheter manipulations were the major risks factors contributing to the increased risk of CPI in these patients.
There is a paucity of data about port infection in HNC patients. Bos et al 19 recently reported an increased rate of port infection in patients with HNC compared with nonHNC (0.68 per 1000 catheter days vs. 0.21 per 1000 catheter days, respectively, p < 0.001). In the current study, the rate of infection for HNC patients was similar (0.53 per 1000 catheter days). Unlike hematological cancer, the definite risk factors for CPI have not been identified in HNC patients. The authors assume multiple factors may be pertinent to the increased risk of infection: (1) HNC patients undergoing radical surgery and concurrent chemoradiation usually are associated with malnutrition and impaired immune function. Poor oral intake necessitates the increased use of parenteral nutrition, further increasing the risk of blood stream infections; (2) it is noteworthy that patients with HNC have a higher incidence of infection compared with patients with other malignancies because microbes are more likely to colonize in the oral cavity and the skin surrounding the insertion site; 20 and (3) platinum remains the standard regimen for HNC but has been reported to carry a high risk of cumulative myelosuppression and catheter-related systemic infections. 21e23 Nevertheless, a further prospective study is warranted to validate the role of these factors in central port infections.
It is notable that the incidence of CPI was lower in patients who were receiving adjuvant/neoadjuvant chemotherapy than in those receiving chemotherapy in nonadjuvant settings. Although the mechanism is unclear, this observation may be attributable to an early tumor stage, more integral immunity, and fewer hospitalizations in patients with adjuvant settings. Pseudomonas aeruginosa and Candida were the most common pathogens in the current studyeboth are known to be predominant nosocomial pathogens in hospital settings. Other studies were in agreement with the current result that Gram-negative bacteria has become the most common pathogen for CPI in recent decades. 6, 12 Staphylococcus supp. was the second most common pathogen. These Gram-positive cocci are known to colonize in the skin, yet the association between frequent punctures and CPI has not been established. In the current study, an increased risk for CPI in the patients who received more cycles of chemotherapy was not observed.
This study consisted of Chinese cancer patients and has a relatively larger sample size compared with other similar studies. The authors hope this study could offer important information to prevent Asian patients from CPI. In conclusion, infection remains a challenging issue for total implantable central venous ports. Implementation of an insertion bundle for preventing central line-associated bloodstream infections is warranted, especially for those patients with hematological and head and neck cancers, as well as for patients receiving chemotherapy in the metastatic settings.
